# Johnson & Johnson Moat

Status: published. Policy: company-analysis-1.

The passages support a narrow moat based on product differentiation and intellectual property, with demonstrated adoption, product upgrades and some realized pricing support. They do not establish exceptional durability or a wide company-wide advantage. STELARA sales erosion, procurement pressure and competition show meaningful limits. Pricing power is selective rather than unrestricted.

## intangible_assets

Differentiated medical products and intellectual property support a current, product-specific advantage. Shockwave adoption, Wound Closure upgrades and continued ACUVUE OASYS 1-Day performance provide operating evidence beyond management's general innovation claims. Strategic price actions contributed to contact-lens growth. Patent disclosures support an exclusion mechanism, but the passages do not establish remaining exclusivity by product.

Durability: A narrow advantage is supported across selected franchises, but its duration cannot be established. Continued innovation and successful commercialization are necessary to replenish advantages as products face competition or lose protection. Clinical-stage acquisitions and the planned Orthopaedics separation represent potential benefits rather than demonstrated extensions of the moat.

Risks: STELARA sales decline already adversely affected product mix. Surgery and Vision face disclosed competitive pressure, while China volume-based procurement offsets growth. Patent challenges and regulated pharmaceutical pricing constrain exclusivity and monetization. These risks are distinct from demonstrated erosion: generic risk disclosures alone do not establish realized losses.

Invalidation: The thesis would fail if subsequent operating disclosures showed sustained declines in adoption and upgrades across the cited differentiated portfolios, price actions reversing without demand support, or losses following patent challenges that replacement products could not offset. Persistent procurement-driven deterioration across these franchises would also undermine the claimed advantage.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm](https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm) · 2026-02-11
- [https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm](https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm) · 2026-07-23
- [https://www.sec.gov/Archives/edgar/data/200406/000020040626000063/jnj-20260309.htm](https://www.sec.gov/Archives/edgar/data/200406/000020040626000063/jnj-20260309.htm) · 2026-03-11

[JSON](https://beanvest.com/stock/jnj/moat.json)